The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Updates in the management of lung cancer with ADCs
Timothy Burns, MD, PhD, University of Pittsburgh & UPMC Hillman Cancer Center, Pittsburgh, PA, comments on the emerging role of antibody-drug conjugates (ADCs) in lung cancer. MET-targeting ADCs have been promising in patients with EGFR-mutant lung cancer as monotherapy or with existing tyrosine kinase inhibitors. Trastuzumab deruxtecan has additionally been approved in the second-line setting and trials are underway to assess the ADC in the first-line setting. Dr Burns also comments on datopotamab deruxtecan and sacituzumab govitecan. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
